A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial.
Akiko Hisamoto
No relevant relationships to disclose
Jiichiro Sasaki
No relevant relationships to disclose
Nagio Takigawa
Honoraria - AstraZeneca; Sanofi
Yoshiyuki Shioyama
No relevant relationships to disclose
Junji Kishimoto
No relevant relationships to disclose
Mitsuhiro Takemoto
No relevant relationships to disclose
Katsuyuki Hotta
Honoraria - AstraZeneca; Nippon Kayaku; Sanofi
Mitsune Tanimoto
No relevant relationships to disclose
Yukito Ichinose
No relevant relationships to disclose
Katsuyuki Kiura
Honoraria - AstraZeneca; Nippon Kayaku; Sanofi